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Abstract 
Influenza outbreaks are associated with significant morbidity.
Our aim was to determine the factors associated with increased
mortality in hospitalized patients admitted with diagnosis of
influenza, at a tertiary care center in Pakistan. This study included
all adult patients with an influenza infection, confirmed by real-
time reverse-transcriptase polymerase-chain-reaction (RT-PCR) at
Aga Khan University Hospital Pakistan. In our study, 112 patients
with laboratory-confirmed influenza virus infection were admitted
at our hospital from the 1st of January 2013 to the 31st of
December 2018. Eighty-nine patients (79.46%) were managed in
ward or special care units and 23 patients (20.5%) received treat-
ment in intensive care unit (ICU). The overall mortality in our
study was 15/112 (13.4%) with the mortality rate of ICU patients
being 47.8% while the mortality rate of patients treated in special
care units and wards was only 4.5%. The mean age of patients
with influenza infection was 58.1 years (±16.6). Influenza virus
type A was found in 87 patients (77.6%), while influenza type B
was present in only 25 (22.4%) patients. Out of the 15 non-sur-
vivors, 14 had influenza A. Only 17 patients (15.2%) were found
to have positive culture of respiratory specimen, out of which 3
were non-survivors and 14 were survivors. Our analysis identified
septic shock (odds ratio 45.24; 95%, confidence interval 6.20-330;
p<0.001), renal failure (odds ratio 10.88; 95%, confidence interval
1.61-73.52; p=0.01) and ICU stay (odds ratio 17.22; 95%, confi-
dence interval 2.68-110.5; p=0.003) as independent risk factors
associated with in-hospital mortality.
Introduction
Influenza, commonly known as flu is an infection caused by
influenza virus which is an RNA virus belonging to
Orthomyxoviridae family [1]. Most of the epidemic of influenza is
usually caused by two types of viruses, influenza A and influenza
B. Influenza A is further subcategorized into subtypes e.g.,
influenza A (H1N1) viruses, influenza A (H3N2) viruses based on
characteristics of two surface antigens, hemagglutinin (HA) and
neuraminidase (NA) [2]. The spectrum of disease from influenza
virus ranges from mild flu like illness to acute respiratory distress
syndrome (ARDS). Annual epidemics caused by influenza virus
are not only a major burden to health care resources, but also asso-
ciated with high mortality rates [3]. Globally, 3-5 million cases of
influenza are reported per annum and the estimated global mortal-
ity rate is between 291,243-645,832 per year [4]. During 2017-
2018 influenza season the overall influenza related mortality in
Europe was estimated to be 25.4 (95% CI 25.0-25.8) per 100,000
population [5].
The burden of disease in Asia is much higher than Europe.
Eleven thousand seven hundred thirty-four (11,734) laboratory-
confirmed influenza cases were reported in 19 Asian countries
between 2010-2017 [6]. In 2015, about more than 30,000 cases
and 1731 deaths were reported in India alone [7]. In a laboratory-
based influenza surveillance study conducted between 2007 and
2017 a total of 3475 influenza cases were detected in Pakistan. In
2017, influenza related death from Pakistan was reported to be 2.0
per 100,000 [8,9]. Despite the annual epidemics of influenza in
Pakistan there have been very few studies done on the disease
from our country. To be better prepared to handle influenza epi-
demics and to decrease the mortality rates associated with the dis-
ease, it is of paramount importance to know the predictors of mor-
tality of influenza. Respiratory failure is the major cause of mor-
tality in patient with influenza infection [10]. A study from India,
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during influenza outbreak of 2015 showed that the requirement of
intubation was the only significant predictor of mortality related to
the disease [11]. In a meta-analysis, which included 600,000
patients, risk factors for influenza associated mortality were age,
atrial fibrillation and pneumonia [12].
To our knowledge, there is no published five-years study from
Pakistan on predictors of influenza related mortality. The purpose
of this study is to identify factors associated with mortality in hos-
pitalized influenza over a period of five years at tertiary care hos-
pital in Pakistan.
Methodology
We conducted a retrospective cross-sectional study from
January 13-December 18, at Aga Khan University Hospital in
Pakistan which is a 750 bedded JCIA accredited tertiary care hos-
pital. We included patients aged 18 and above, of both sexes, who
had symptoms of influenza like illness (temperature of 37.8°C or
higher along with cough or sore throat) confirmed by Real-time
Reverse-Transcriptase Polymerase Chain-reaction (RT-PCR).
Nasal swabs were taken under aseptic precautions of all patients
admitted with influenza like illness.
Clinical data was collected from review of patient’s daily
records. Radiological and laboratory data were obtained from elec-
tronic records. Data was collected regarding baseline demograph-
ics, symptoms at time of admission, oseltamivir prescription,
antibiotics, any positive cultures (blood, sputum, and urine), hos-
pital and Intensive Care Unit (ICU) length of stay. All the interven-
tions undertaken like invasive and non-invasive ventilation, renal
replacement therapy, use of vasopressors, and cases of septic shock
were recorded. Data was also obtained for the oxygen require-
ments, development of ARDS and use of steroids. Data regarding
development of complications and clinical outcome at discharge
was also collected. Ethical review committee of Aga Khan
Hospital had approved the study. 
Statistical analysis
A descriptive analysis was done for demographic and clinical
features. The results were presented as mean ± SD for quantitative
variables and numbers (percentage) for qualitative variables.
Differences in proportions, between survivors and non-survivors,
were assessed by using the Chi-square test or Fisher exact test
where appropriate. To assess univariate associations between the
outcomes and potential predictors, odds ratios (ORs) and their 95%
confidence intervals (CIs) were computed by logistic regression
analysis. All p-values were two sided and considered as statistical-
ly significant if <0.05. All significant factors on univariate analysis
were considered for inclusion in the multivariable logistic model.
All analyses were conducted by using the SPSS software,
release 16.0. 
Results
In our study, 112 patients with laboratory confirmed influenza
virus infection were admitted at our hospital from 1st January 2013
to 31st December 2018. Eighty-nine patients (79.46%) were man-
aged in ward or special care units and 23 patients (20.5%) received
treatment in ICU. Although the overall mortality in our study was
13.4%, the mortality rate of patients admitted in ICU with influen-
za was 47.8%. The mean age of patients with influenza infection
was 58.1 years (±16.6). The majority of patients (42% of the total
number) were between 60 and 75 years of age but the 40-60 years
age group was found to have the highest mortality rate (23.33%).
Even though 62.5% (70/112) of all patients were female, male
patients had higher mortality (19.02%v/s 10%). Fourteen patients
were pregnant and all but one of them survived.
A total of 72 out of 112 patients (64.2%) had at least one co
morbid illness. Hypertension (n=54, 48.2%) and Diabetes (n=51,
45.5 %) were two most common comorbid conditions in our study
population. Other co-morbid observed were, chronic lung diseases
(n=32, 28.6%), heart disease (n=18, 16.1%) and renal impairment
(n=12, 10.71%), while neurological diseases were present in only
4 patients (3.5%) (Figure 1). Among all co-morbid conditions,
heart diseases were the only one which were more prevalent in
non-survivors (4/15, 26.7%) compared to survivors (14/89, 14.4%;
the results though were not statistically significant). The time
between onset of symptoms and hospital admission ranged from 1-
25 days, with a median of 5 days. It was 5.1±2.7 days in survivors
and 7±5.2 days in non-survivors. Fever (93%) and cough (90%)
were the most common symptoms, followed by shortness of breath
(61%). The clinical presentations were equally distributed among
survivors and non-survivors. Only 20 patients (17.9%) received
invasive mechanical ventilation, out of which 10 died. Forty
patients received non-invasive ventilation.
Influenza virus type A was found to be the most common strain
of influenza in this setting. Eighty-seven patients (77.6%) were
positive for influenza type A, while influenza type B was present
in only 25 (22.4%) patients. Out of the 15 non-survivors, 14 had
influenza A.
Only 17 patients (15.2%) were found to have positive culture
of respiratory specimen, out of which 3 were non-survivors and 14
were survivors. Staphylococcus aureus was the most common iso-
lated organism (37% of overall culture positive organism), fol-
lowed by Aspergillus spp. (29% of overall culture positive organ-
ism). Among non-survivors, two patients had sputum culture pos-
itive for Acinetobacter and 1 had positive sputum culture for H.
influenzae. All patients received oseltamivir and the mean duration
between the onset of symptoms and the initiation of therapy was
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5.3±3.3 days. Delay in the initiation of oseltamivir was associated
with increased complications.
The most common influenza related complications that were
observed in our study was secondary bacterial pneumonia (65%)
followed by acute renal failure (30%). Among survivors, renal fail-
ure was present in 24/89 (26.96%) patients and among non-sur-
vivors, it was present in 10/15 (66.66%) patients. ARDS was
reported in 16/112 (14 %) of the patients, out of which 9 were non-
survivors. Seventeen patients (15%, of total influenza patients)
were diagnosed with septic shock and it was found to be more
prevalent in non-survivors. Eleven out of fifteen (73.33%) non-
survivors were found to have septic shock, while amongst sur-
vivors, only 6/89 (6.74%) had the complication. Cardiac complica-
tions, as a group were present in 27 patients (24.1%) among which
16 patients had acute coronary syndrome; among these patients 12
were survivors and 4 were non-survivors. Eleven patients devel-
oped arrhythmias during their hospital stay and only one of them
was a non-survivor. Steroids were given to 61 patients (54.5%), out
of which, 10 of them were non-survivors (66.66%). The average
length of a hospital stay for a non-survivor was 12.23±7.8 days,
while that of survivor was 6.53±6.1 days. The length of ICU stay
was also longer for non-survivors as compared to survivors
(10.23±6.6 days vs 7.73±5.8 days).
Univariate and multivariate logistic regression was used to
identify predictors of mortality in influenza (Table 1). The length
of hospital stays (p=0.01), prolonged duration between the onset of
illness and hospital admission (p=0.03), the length of ICU stays
(p<0.001), invasive ventilation (p<0.001), ARDS (p=0.001), respi-
ratory failure (p=0.008), septic shock (p<0.001) and acute renal
failure (p<0.001) were considered to be significant in the univari-
ate analysis. The multivariate analysis identified septic shock
(odds ratio 45.24; 95%. confidence interval 6.20-330; p<0.001),
renal failure (odds ratio 10.88; 95%. confidence interval 1.61-
73.52; p=0.01) and ICU stay (odds ratio 17.22; 95%. confidence
interval 2.68-110.5; p=0.003) as independent risk factors associat-
ed with in-hospital mortality (Table 2).
Discussion
This study reported on a series of hospitalized patients with
laboratory confirmed influenza infection, from January 2012-
December 2018, at a tertiary care hospital. The overall mortality
rate in our study was found to be 13.4%, which is comparable to
similar studies done globally and also from other countries in
region [12]. The ICU stay, along with the presence of septic shock
and acute renal failure, were found to be strong predictors of mor-
tality in our hospitalised patients with influenza. In this study,
20.5% of the influenza patients received treatment in the ICU
which is found to be higher than the number reported in the litera-
ture [13,14]. As our hospital’s ICU only admits patients requiring
invasive mechanical ventilation and level 3 care, the mortality
rates are therefore indicative of severity of the disease, leading to
ARDS and the need of mechanical ventilation. The ICU mortality
rate in this study was found to be 47.8% which is higher than other
ICU mortality rates observed worldwide [14-17]. Our ICU patients
were older with average age of 66, with diabetes and hypertension
in 2/3rd of them, which might be contributing, to high mortality.
This indicates that, severe form of influenza is associated with high
mortality, compared to milder form of the disease. Septic shock in
our study was found to be a very strong predictor of mortality in
influenza patients, being present in 11 out of 15 patients (73.33%)
who did not survive compared to only 6% of survivors. Difficult
management of septic shock, in the presence of worsening hypox-
emia and ARDS seems to be the likely reason behind these results
[18]. This association between septic shock and influenza, though
was not directly compared in previous studies done globally but
reported in literature [19,20,22].
In our study 10/15 that is 66.66% of non-survivors had renal
failure. This appeared to be another strong predictor of influenza
mortality, as is also shown, in most of the studies done globally
[22-24]. The mortality rate was higher in middle-aged group, in
spite of the lower incidence in current study. This is consistent
with results of the previous studies, which also showed higher
mortality among middle aged group [25,26]. We need further
large-scale investigations to identify the true relationship
between age group and influenza mortality In our study, females
had lower mortality rates compared to males, even though the
majority of the influenza patients were females. Although previ-
ous literature regarding influenza related complications showed
higher mortality in male patients as compared to female, it would
be inappropriate to assume association of male gender with
increased risk of mortality due to non-availability of sufficient
epidemiological data [27,28]. Time from onset of symptoms to
hospital admission was found to be associated with increased risk
of mortality in our study. Delay in seeking medical care with
severe influenza, hence resulting in late initiation of antiviral
therapy are associated with poor outcomes [29,30]. This is also
signifying a lack of primary and secondary care facilities in our
country, where patients are instead brought to tertiary care facil-
ities, with more severe and advance stage of disease. In present
study, only 17 patients had positive sputum culture for secondary
bacterial or fungal infection. This could be attributed to early ini-
tiation of empirical antibiotics at our institute. Staphylococcus
Aureus, as expected, was the commonest organism isolated,
which is in line with all previous reports [31,32]. Similarly, fun-
gal infections were also found to be the second highest reported
infection, in our study. Influenzas infection is a risk factor for
invasive pulmonary aspergillosis even in immunocompetent
patients and can lead to invasive disease [33,34]. The pathogen
Aspergillus fumigatus was isolated in 5 out of 17 culture positive
patients. All patents with Aspergillus isolated in respiratory
secretion had underlying obstructive airway diseases. This find-
ing can therefore be due to colonization of respiratory tract by the
organism, as all patients improved without any antifungal thera-
py. The high incidence of co-infections might be result of some
immune defect in these patients, making them more susceptible
to acquire these infections.
Our study has few limitations. It is a single centre study done
at a tertiary care university hospital. The number of cases is there-
fore limited, and they are also more severe in intensity as com-
pared to cases in district hospitals. The findings observed from this
university hospital study might not be generalizable to other hos-
pitals. The lack of disease severity scoring system like APACHE or
SOFA makes it difficult to truly ascertain the risk of mortality in
these patients. Being a retrospective study, we might have some
inadequate data. Our sample size was small, and the results
observed might change if the study is done with a larger sample
size. 
Despite the above limitations, our study has shown novel find-
ings about mortality prediction in hospitalized influenza patients
during five-years period. The mortality of influenza in our institute
was 13% but it reached a significantly high percentage of 47.2% in
severe influenza patient requiring mechanical ventilation and ICU
admissions.
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Table 1. Predictors of mortality in influenza.
                                                                            Survivors (n=97)                          Died (n=15)                                         p
Age (years)                                                                                        57.9±17.6                                                 59.5±17.6                                                        0.72
Gende                                                                                                                                                                                                                                             0.17
Male                                                                                                   34 (35.1)                                                   8 (53.3)
Female                                                                                              63 (64.9)                                                   7 (46.7)                                                             
Body mass index                                                                               27.3±9.0                                                   25.0±2.9                                                         0.35
Duration, illness-admission                                                            5.1±2.7                                                     7.0±5.2                                                         0.03*
Length of ICU stay                                                                             7.7±5.8                                                    10.2±6.6                                                        0.33*
Length of stay                                                                                     6.5±6.1                                                    12.2±7.8                                                        0.01*
Comorbidities                                                                                                                                                                                                                                  
Diabetes mellitus                                                                           45 (46.4)                                                     6 (40)                                                           0.64
Hypertension                                                                                   46 (47.4)                                                   8 (53.3)                                                         0.67
Asthma                                                                                              12 (12.4)                                                   2 (13.3)                                                         0.91
Chronic lung disease                                                                     15 (15.5)                                                     3 (20)                                                           0.65
Heart disease                                                                                  14 (14.4)                                                   4 (26.7)                                                         0.23
Kidney disease                                                                                11 (11.3)                                                    1 (6.7)                                                          0.58
Liver disease                                                                                     3 (3.1)                                                           0                                                               0.49
Neurology disease                                                                           4 (4.1)                                                           0                                                               0.42
Immunosuppression                                                                       6 (6.2)                                                           0                                                               0.32
Blood disease                                                                                    1 (1.0)                                                     2 (13.3)                                                         0.04
Pregnancy                                                                                         13 (13.4)                                                    1 (6.7)                                                          0.68
Symptoms                                                                                                                                                                                                                                         
Fever                                                                                                 90 (92.8)                                                  14 (93.3)                                                        0.93
Cough                                                                                                87 (89.7)                                                  14 (93.3)                                                        0.99
Sputum                                                                                             38 (39.2)                                                   5 (33.3)                                                         0.66
Myalgia                                                                                              14 (14.4)                                                   3 (20.0)                                                         0.69
Headache                                                                                           2 (2.1)                                                           0                                                               0.99
Diarrhoea                                                                                           7 (7.2)                                                       3 (20)                                                           0.13
Nausea and vomiting                                                                       8 (8.2)                                                      1 (6.7)                                                          0.99
Confusion                                                                                           1 (1.0)                                                      1 (6.7)                                                          0.25
Dyspnoea                                                                                          58 (59.8)                                                  10 (66.7)                                                        0.61
Hypotension                                                                                      5 (5.2)                                                     2 (13.3)                                                         0.23
Muscle weakness                                                                             6 (6.2)                                                           0                                                               0.99
General weakness                                                                            8 (8.2)                                                           0                                                               0.59
Upper respiratory tract infection symptoms                          29 (29.9)                                                   4 (26.7)                                                         0.99
Arrhythmia                                                                                         7 (7.2)                                                     6 (40.0)                                                        0.002
Influenza type
A                                                                                                         73 (75.3)                                                  14 (93.3)
B                                                                                                         24 (24.7)                                                    1 (6.7)                                                          0.18
ICU stay                                                                                               12 (12.4)                                                  11 (73.3)                                                      <0.001
Ventilation                                                                                          10 (10.3)                                                  10 (66.7)                                                      <0.001
Procalcitonin                                                                                      4.7±13.5                                                  12.6±13.5                                                       0.04*
Treatment                                                                                                                                                                                                                                          
Steroid                                                                                              51 (52.6)                                                  10 (66.7)                                                        0.30
TA/sputum positive                                                                           14 (17.7)                                                   3 (27.3)                                                         0.42
Bacterial pneumonia                                                                        56 (57.7)                                                  11 (73.3)                                                        0.25
Exacerbation of underlying disease                                            14 (14.4)                                                    1 (6.7)                                                          0.68
Respiratory failure                                                                           19 (19.6)                                                   8 (53.3)                                                        0.008
Acute respiratory distress syndrome                                            9 (9.3)                                                     7 (46.7)                                                        0.001
Pneumothorax                                                                                     3 (3.1)                                                           0                                                               0.99
Pulmonary disease                                                                           13 (13.4)                                                    1 (6.7)                                                          0.68
Acute coronary syndrome                                                              11 (11.3)                                                   5 (33.3)                                                         0.03
Arrhythmias                                                                                          7 (7.2)                                                      1 (6.7)                                                          0.99
Sepsis/septic shock                                                                           6 (6.2)                                                    11 (73.3)                                                      <0.001
Acute kidney injury                                                                            23 (24)                                                    11 (73.3)                                                      <0.001
Cerebrovascular accident                                                                 2 (2.1)                                                           0                                                               0.99
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Conclusions
Our study has showed that development of concomitant septic
shock and renal failure increases the odds of mortality in influenza
patients. This finding might help clinicians in more vigilant care of
these patients with earlier ICU transfers and probable use of inva-
sive hemodynamic monitoring devices in management of these
patients.
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